Latest News and Press Releases

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for...

Tiny Health appoints Dr. Elisa Song as Chief Medical Officer and Dr. Taylor Sittler as Board Director to strengthen its practitioner-focused strategy.

Foundation for Sarcoidosis Research appoints fourteen new members to serve the organization’s Scientific Advisory Board.

Partnership expands access to comprehensive at-home microbiome testing, aiming to address health issues at the root cause

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...

Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients

FSR Launches Say Sarcoidosis campaign for April's Awareness Month

26 Patient Volunteer Leaders joined the Foundation for Sarcoidosis Research at Cleveland Clinic for the Leadership Advanced Training Conference

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Tiny Health, the first at-home gut microbiome test developed for babies, today announced a $8.5 million Series A round led by Spero Ventures,...